FDA Approves Selpercatinib for Lung & Thyroid Cancers with RET Mutations or Fusions
On May 8, 2020, the U.S. Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo, Eli Lilly and Company) for the following indications:
Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC);
Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy;
Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
In Person Meeting & NetworkingMay 6, 2026 at 8:00 AM EDT560 King Street, Charleston, SC, USAHyatt Place + Hyatt House Charleston - Historic District, Charleston
Precision in Practice: Translating MRD Into Oncology Care
In Person Conference & ConventionApril 28, 2026 at 5:30 PM EDT1020 South Calhoun Street, Fort Wayne, IN, USAHilton Fort Wayne at the Grand Wayne Center, Fort Wayne
In Person Conference & ConventionApril 28, 2026 at 5:15 PM CDT1111 East Broadway, Columbia, MO, USAThe Broadway Columbia (A DoubleTree by Hilton), Columbia
